ValuEngine upgraded shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) from a sell rating to a hold rating in a research report report published on Tuesday.

Separately, HC Wainwright reaffirmed a buy rating on shares of Asterias Biotherapeutics in a report on Wednesday, August 16th.

Shares of Asterias Biotherapeutics (AST) opened at 3.45 on Tuesday. The company’s 50-day moving average is $3.37 and its 200-day moving average is $3.37. The company’s market cap is $172.42 million. Asterias Biotherapeutics has a 12-month low of $2.83 and a 12-month high of $5.80.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.